CG Oncology (CGON) Non-Current Assets (2023 - 2026)

CG Oncology's Non-Current Assets history runs 4 years deep, the most recent figure standing at $33.1 million for Q1 2026.

• Quarterly Non-Current Assets rose 22.71% year-over-year to $33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $127.8 million (up 349.39% YoY) and the FY2025 annual result came in at $32.1 million, up 5371.38% from the prior year.
• Non-Current Assets was $33.1 million for Q1 2026 at CG Oncology, up from $32.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $34.1 million in Q3 2025 and bottomed at $391000.0 in Q3 2024.
• A 4-year average of $16.2 million and a median of $16.1 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 88.66% — and 2025, when it jumped 8627.11%.
• CG Oncology's Non-Current Assets stood at $5.2 million in 2023, then tumbled by 88.66% to $587000.0 in 2024, then surged by 5371.38% to $32.1 million in 2025, then increased by 3.12% to $33.1 million in 2026.
• Business Quant data shows CGON's Non-Current Assets at $33.1 million in Q1 2026, $32.1 million in Q4 2025, and $34.1 million in Q3 2025.